New government plan to speed up elimination of cervical cancer
The central government has outlined a long-term plan to accelerate the elimination of cervical cancer by 2030 via an initiative aimed at boosting vaccination rates among girls.
February 8, 2023
by www.gov.cn
Cemiplimab Prolongs Survival in Recurrent Cervical Cancer
For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab....
February 10, 2022
by drugs.com
New NCCN Guidelines help Patients Better Understand and Participate in the Care of their Cervical Cancer
The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Cervical Cancer to help people with cervical cancer become more informed...
December 14, 2021
by prnasia
HPV Vaccine Is Reducing Cervical Cancers in Teens, Young Women
The first wave of girls to receive the HPV vaccine are much less likely to contract or die from cervical cancer than women just a few years older, a new study reports.
December 1, 2021
by Drugs
Could a Single Dose of the HPV Vaccine Be Enough?
Women getting vaccinated against the cancer-causing human papillomavirus (HPV) now need two or three shots, but an African clinical trial suggests a single dose is just as effective.
November 29, 2021
by Drugs
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab...
September 28, 2021
by prnasia
Gap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by Enough
Racial disparities in breast cancer survival have narrowed in recent years, but Black women with the disease still have double the death rate of white women.
July 5, 2021
by drugs
Women's Cancer Screenings Plummeted During Pandemic
Breast and cervical cancer screenings dropped sharply among low-income minority women during the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention says.
July 1, 2021
by drugs
Agenus BLA for Balstilimab as Treatment for Cervical Cancer Granted Priority Review by U.S. FDA
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents including checkpoint antibodies, cell therapies, adjuvants, and vaccines that activate immune response to cancers and infections announced that the U.S. FDA accepted Agenus’ ...
June 18, 2021
by americanpharmaceuticalreview
ASCO: Incidence of Cervical Cancer Has Decreased in the United States
The incidence of cervical cancer has decreased, while the incidence of other human papillomavirus (HPV), according to a study scheduled to be presented at the annual meeting of the American Society of of Clinical Oncology, held virtually from June 4 to 8.
June 2, 2021
by drugs
HPV Vaccination Is Lowering U.S. Cervical Cancer Rates
In a finding that offers the first evidence that the human papillomavirus (HPV) vaccine is indeed protecting women from cervical cancer, new research shows cases in the United States have slowly but steadily declined over the last decade and a half.
May 20, 2021
by drugs
Libtayo Monotherapy Trial in Advanced Cervical Cancer Stopped Early for OS Positive Result
Regeneron Pharmaceuticals and Sanofi announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) monotherapy compared to chemotherapy, in patients previously ...
March 22, 2021
by americanpharmaceuticalreview